Filtered By:
Procedure: Hemodialysis
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 41 results found since Jan 2013.
Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease
CONCLUSIONS: Due to the higher antibody levels induced by HepB-CpG in participants with CKD, seroprotection against HBV may be expected to persist longer than that induced by HepB-Eng.CLINICALTRIALS: gov: NCT01282762.PMID:37085451 | DOI:10.1016/j.vaccine.2023.04.028
Source: Vaccine - April 21, 2023 Category: Allergy & Immunology Authors: Matthias Girndt Patricia Houser Roberto Manllo-Karim John E Ervin Chaim Charytan Stephen Chow Margarita Symonian-Silver Lawrence Lehrner Douglas Linfert Douglas Shemin Ann Michelsen Fang Xie Robert S Janssen Source Type: research
Seroconversion following Heplisav-B, hepatitis B vaccine (recombinant), adjuvanted, in patients with end-stage renal disease at an urban safety net hospital
CONCLUSION: Patients with ESRD who received three 20-μg doses of recombinant HBV vaccine had a seroconversion rate of 83%, representing a similar seroconversion rate and fewer doses of vaccine as compared to the standard HBV vaccine regimen for patients with ESRD.PMID:36681904 | DOI:10.1093/ajhp/zxad022
Source: American Journal of Health-System Pharmacy : AJHP - January 22, 2023 Category: Drugs & Pharmacology Authors: Connor Walsh Kathryn McDaniel Lindsey Lindsey Sarah Johnson Ted Walton Source Type: research
Serological and molecular characterization of hepatitis B virus infection in chronic kidney disease patients from Rio de Janeiro, Brazil
The objective of this cross-sectional study was to evaluate the frequency of serological markers for hepatitis B, and the occurrence of overt and occult HBV infection (OBI) and its molecular characterization in serum samples from 644 CKD patients in HD units located in Rio de Janeiro, Brazil, from 2013 to 2017. HBV DNA was investigated in HBsAg reactive and "anti-HBc alone" samples to determine infecting genotypes and genetic relatedness between sequences. The prevalence of serological markers HBsAg+, anti-HBc alone, anti-HBc+/anti-HBs+, anti-HBs+, anti-HBc/anti-HBs/HBsAg were 5.9%, 2.8%, 30.7%, 26.6%, 34.0%, respectively....
Source: Braz J Infect Dis - June 6, 2022 Category: Infectious Diseases Authors: Livia Melo Villar Ketlyn Araujo Fraga Ana Carolina da Fonseca Mendon ça Juliana Cust ódio Miguel Elisangela Ferreira da Silva Jakeline Ribeiro Barbosa Paulo S érgio Fonseca de Sousa Lia Laura Lewis-Ximenez Francisco Campello do Amaral Mello Source Type: research
Prevalence of Hepatitis B and Hepatitis C in Patients undergoing hemodialysis at a teaching hospital in Uttarakhand
CONCLUSION: In HD patients, viral hepatitis poses a significant health hazard, particularly in developing countries. HBV vaccination, strict adherence to the universal precautions, segregation of HBV-positive patients can control HBV infection in HD units. However, for HCV, the absence of a specific vaccine and the nosocomial transmission of the virus increase the peril more.PMID:35516698 | PMC:PMC9067204 | DOI:10.4103/jfmpc.jfmpc_1017_21
Source: Primary Care - May 6, 2022 Category: Primary Care Authors: Dimple Raina Neha Rawat Ajay K Pandita Source Type: research
Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep)
CONCLUSION: In this small pilot study, high-dose oral cholecalciferol supplementation did not improve the hepatitis B vaccination response in haemodialysis patients with vitamin D insufficiency. This clinical trial was registered within EudraCT (EudraCT number 2011-004621-26).PMID:34802788 | DOI:10.1016/j.vaccine.2021.11.029
Source: Vaccine - November 22, 2021 Category: Allergy & Immunology Authors: Hildegard Hafner-Giessauf Sabine Horn Gerold Schwantzer Hannelore Sprenger-M ähr Karl Lhotta Alexander R Rosenkranz Emanuel Zitt Source Type: research
End-Stage Renal Disease: Medical Management
Am Fam Physician. 2021 Nov 1;104(5):493-499.ABSTRACTEnd-stage renal disease (ESRD) is diagnosed when kidney function is no longer adequate for long-term survival without kidney transplantation or dialysis. Primary care clinicians should refer people at risk of ESRD to nephrology to optimize disease management. Kidney transplantation typically yields the best patient outcomes, although most patients are treated with dialysis. The decision to initiate dialysis is best made through shared decision-making. Because most patients with ESRD elect to receive hemodialysis, the preservation of peripheral veins is important for those...
Source: American Family Physician - November 16, 2021 Category: Primary Care Authors: Noah Wouk Source Type: research
